BIOLASE Reports Findings From 12-Month Follow-up To Clinical Trial Performed At The McGuire Institute
Portfolio Pulse from Benzinga Newsdesk
BIOLASE has reported findings from a 12-month follow-up to a clinical trial performed at The McGuire Institute. The study confirms that BIOLASE's Waterlase REPAIR® Perio protocol has similar and sustainable clinical outcomes as compared to traditional MIST in treating intrabony defects.
November 08, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the 12-month follow-up to a clinical trial of BIOLASE's Waterlase REPAIR® Perio protocol could potentially boost investor confidence in the company.
The positive results from the clinical trial of BIOLASE's Waterlase REPAIR® Perio protocol reaffirm the product's clinical efficacy. This could potentially lead to increased demand for the product, which would positively impact the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100